Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer

被引：0
作者：
Suguru Yamada
Tsutomu Fujii
Yukihiro Yokoyama
Hiroki Kawashima
Osamu Maeda
Kojiro Suzuki
Tohru Okada
Eizaburo Ono
Junpei Yamaguchi
Nao Takano
Hideki Takami
Masamichi Hayashi
Yukiko Niwa
Yoshiki Hirooka
Yoshiyuki Ito
Shinji Naganawa
Yuichi Ando
Masato Nagino
Hidemi Goto
Yasuhiro Kodera
机构：
[1] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery (Surgery II)
[2] University of Toyama,Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences
[3] Nagoya University Graduate School of Medicine,Division of Surgical Oncology, Department of Surgery
[4] Nagoya University Graduate School of Medicine,Department of Gastroenterology and Hepatology
[5] Nagoya University Hospital,Department of Clinical Oncology and Chemotherapy
[6] Aichi Medical University,Department of Radiology
[7] Nagoya University Graduate School of Medicine,Department of Radiology
[8] Nagoya University Hospital,Department of Endoscopy
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
Phase I study; Gemcitabine; Nab-paclitaxel; Radiation; Unresectable locally advanced pancreatic cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：815 / 821
页数：6
相关论文
共 50 条
  • [21] Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma
    Nebot-Villacampa, Maria-Jose
    Zafra-Morales, Ricardo
    Alfaro-Olea, Ascension
    Marin-Gorricho, Raquel
    Casajus-Navasal, Andrea
    Uriarte-Pinto, Moises
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 603 - 611
  • [22] Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer
    Ibusuki, Mayu
    Inoue, Tadahisa
    Kitano, Rena
    Sakamoto, Kazumasa
    Kimoto, Satoshi
    Kobayashi, Yuji
    Ohashi, Tomohiko
    Sumida, Yoshio
    Nakade, Yukiomi
    Ito, Kiyoaki
    Yoneda, Masashi
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (01) : 118 - 121
  • [23] Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
    Rogers, Jane E.
    Mizrahi, Jonathan D.
    Xiao, Lianchun
    Mohindroo, Chirayu
    Shroff, Rachna T.
    Wolff, Robert
    Varadhachary, Gauri R.
    Javle, Milind M.
    Overman, Michael
    Fogelman, David R.
    Raghav, Kanwal P. S.
    Pant, Shubham
    McAllister, Florencia
    CANCER MEDICINE, 2020, 9 (15): : 5406 - 5415
  • [24] A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    ONCOLOGIST, 2023, 28 (07) : E575 - E584
  • [25] Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer
    Dong-sheng Zhang
    De-shen Wang
    Zhi-qiang Wang
    Feng-hua Wang
    Hui-yan Luo
    Miao-zhen Qiu
    Feng Wang
    Yu-hong Li
    Rui-hua Xu
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1065 - 1072
  • [26] Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
    Ueno, Hideki
    Ikeda, Masafumi
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako Eguchi
    Furuse, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (03) : 595 - 603
  • [27] Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
    Peterson, Shawn L.
    Husnain, Muhammad
    Pollack, Terri
    Pimentel, Agustin
    Loaiza-Bonilla, Arturo
    Westendorf-Overley, Colleen
    Ratermann, Kelley
    Anthony, Lowell
    Desimone, Philip
    Goel, Gaurav
    Kudrimoti, Mahesh
    Dineen, Sean
    Tzeng, Ching-Wei D.
    Hosein, Peter J.
    ANTICANCER RESEARCH, 2018, 38 (07) : 4035 - 4039
  • [28] A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer
    Rikiya Hasegawa
    Kosuke Okuwaki
    Mitsuhiro Kida
    Hiroshi Yamauchi
    Yusuke Kawaguchi
    Takaaki Matsumoto
    Toru Kaneko
    Eiji Miyata
    Kazuho Uehara
    Tomohisa Iwai
    Masafumi Watanabe
    Takahiro Kurosu
    Hiroshi Imaizumi
    Takashi Ohno
    Wasaburo Koizumi
    International Journal of Clinical Oncology, 2019, 24 : 1574 - 1581
  • [29] Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
    Shi, Zhan
    Yang, Ju
    Kong, Weiwei
    Qiu, Xin
    Lu, Changchang
    Liu, Juan
    Liu, Baorui
    Du, Juan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
    Liu, Ting
    Li, Qing
    Lin, Zhen
    Liu, Chunhua
    Pu, Wei
    Zeng, Shasha
    Lai, Jun
    Cai, Xuebin
    Zhang, Lisha
    Wang, Shuyang
    Chen, Miao
    Cao, Wei
    Gou, Hongfeng
    Zhu, Qing
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 602 - 615
12345